WBR0642
| Author | [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]] |
|---|---|
| Exam Type | USMLE Step 1 |
| Main Category | Microbiology, Pharmacology |
| Sub Category | Infectious Disease |
| Prompt | A pharmaceutical company is manufacturing a novel antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin to counteract the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose? |
| Answer A | RNA methylation inhibitors |
| Answer A Explanation | Inhibition of RNA methylation can, in theory, help decrease resistance to macrolides since it targets the main resistance mechanism. |
| Answer B | Drug acetylation inhibitors |
| Answer B Explanation | Inhibition of acetylation targets the main mechanism of aminoglycoside resistance rather than that of macrolides. |
| Answer C | Beta-lactamase inhibitors |
| Answer C Explanation | Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. |
| Answer D | Drug efflux pump blockers |
| Answer D Explanation | Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. |
| Answer E | Drug adenylation inhibitors |
| Answer E Explanation | Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. |
| Right Answer | A |
| Explanation | [[Explanation::
|
| Approved | Yes |
| Keyword | Antibiotic resistance, Macrolides, Methylation |
| Linked Question | |
| Order in Linked Questions |
